Sciences - Manager Amway Ada, Michigan, United States
Objectives: Most probiotics follow a one-size-fits-all approach, recommending the same strains and doses for everyone. However, gut environments vary widely between individuals, meaning probiotic efficacy can differ significantly. Understanding both gut bacteria and their functional outputs is critical for advancing personalized gut health solutions. The goal of this research was to understand if Pharmaceutical Meta-Analysis Screening (PMAS by HEM Pharma), a cutting-edge technology that tailors probiotics to individual needs could enable probiotic mixtures to be recommended that generate a postbiotic-based health index, enabling precise recommendations for improved gut health.
Methods: At baseline, subjects were evaluated for microbiome diversity and their ability to produce bacterial derived metabolites, in this case short chain fatty acids (SCFAs). Based on this evaluation, these subjects were recommended to consume a tailored probiotic solution that was identified leveraging PMAS. After a 6-month intervention consuming these tailored probiotics, the subjects returned for follow-up evaluation related to their ability to produce SCFAs and to have their microbiome diversity evaluated.
Results: The PMAS methodology was able to accurately predict which probiotic solution an individual should consume to lead to increased SCFA production and increased microbial diversity.
Conclusions: This approach has demonstrated the ability to increase gut microbiome diversity, a key marker of gut health and resilience. Furthermore, it has been validated as a platform to predict variation in soy isoflavone bacterial metabolism during a human clinical trial. These findings underscore the potential of HEM Pharma to provide personalized solutions that go beyond traditional probiotics, leveraging deeper insights into individual gut profiles to optimize health outcomes.
